Friday, 20 Apr 2018

You are here

The RWCS - RheumNow Week in Review - 9 February 2018

Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui. Also featured are uricase treatments for gout, exercise in RA, CVD in lupus, NFC predicting mortality in systemic sclerosis, Uveitis predicting AS and future manpower shortages in rheumatology.

  1. RWCS 2018 meeting – daily podcasts available here:  https://buff.ly/2BPCMrQ  https://buff.ly/2BPCLEi
  2. Phase 2 trial of SEL-212 (pegsiticase with attached rapamycin nanoparticle) sh ows efficacy and tolerability in tophaceous gout (22% flare rate, 2 infusion reactions). #RWCS https://t.co/AXx5HFjCJb
  3. Pegloticase tolerizing regimen in the Triple study shows improved efficacy with initial 3 weekly infusions inducing high zone tolerance https://t.co/js3aFP6Wy5
  4. DANBIO Study in Denmark shows no increase in healthcare utilization/resources when forced to switch to biosimilar. #RWCS @RheumNow https://t.co/Z0QWmW2uik
  5. Dr Bevra Hahn on factors predisposing SLE Pts to C V events- pred>20mg, high dz activity, high CRP plus usual (HTN, DM, male, age, etc) #rwcs https://t.co/HwY3wBG4WZ
  6. 150 mins of moderate or 75 mins of vigorous exercise weekly may improve HAQ and outcomes in RA. #RWCS @RheumNow https://t.co/A8xy9CJ2uq
  7. What is OCD? a rheumatologist would say OsteoChondritis Dessicans - a condition of adolescents & young adults w/ pain, stiffness, catching or effusion, usually the knee. Caused by focal, alterations in subchondral bone causing instability and risk of OA. https://t.co/7GWlNhf44e
  8. 142 pts with active GN due to ANCA-assoc. vasculitis achieved remission in 2 RCTs; post hoc analysis showed 42% had persistent proteinuria & hematuria. But only persistent hematuria was associated with a significantly higher (4 fold) risk of future relapse https://t.co/AxezacEHYe
  9. Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis  
  10. Nailfold Capillaroscopy Portends Mortality risk in Systemic Sclerosis   
  11. Future Shortage of Rheumatologists in the USA   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.